83,400 Shares in Smith & Nephew SNATS, Inc. $SNN Acquired by Paradigm Asset Management Co. LLC

Paradigm Asset Management Co. LLC purchased a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 83,400 shares of the medical equipment provider’s stock, valued at approximately $1,502,000.

Several other hedge funds also recently modified their holdings of the company. AlphaCore Capital LLC bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth $44,000. Huntington National Bank grew its holdings in Smith & Nephew SNATS by 1,837.0% during the third quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 1,341 shares during the period. Smartleaf Asset Management LLC raised its position in Smith & Nephew SNATS by 1,222.3% in the third quarter. Smartleaf Asset Management LLC now owns 2,486 shares of the medical equipment provider’s stock worth $88,000 after acquiring an additional 2,298 shares in the last quarter. Root Financial Partners LLC acquired a new stake in Smith & Nephew SNATS in the 3rd quarter valued at about $102,000. Finally, MAI Capital Management boosted its position in shares of Smith & Nephew SNATS by 24.0% during the 2nd quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock valued at $134,000 after purchasing an additional 846 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Down 4.1%

SNN opened at $34.86 on Friday. The stock has a fifty day moving average of $34.40 and a 200-day moving average of $34.95. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 2.57. Smith & Nephew SNATS, Inc. has a 12-month low of $23.91 and a 12-month high of $38.79.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SNN shares. Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a report on Thursday. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.